Chargement en cours...
Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?
Alzheimer's disease (AD) drug developments and clinical trials (CT) remain vulnerable to problems that undermine research validity. Investigations of CT methods reveal how numerous factors decrease active drug-placebo group differences and increase variance, thereby reducing power to reach stat...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2008
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3372084/ https://ncbi.nlm.nih.gov/pubmed/18953116 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|